Market Summary

Introduction

1.    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2.    Executive Summary
3.    Chronic Urticaria Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4.    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5.    Chronic Urticaria Epidemiology Analysis-7MM
    5.1    Epidemiology Overview (2016-2031)
    5.2    United States Chronic Urticaria Epidemiology (2016-2031)
    5.3    EU-4 and United Kingdom Chronic Urticaria Epidemiology (2016-2031)
    5.4    Japan Chronic Urticaria Epidemiology (2016-2031)
6.    Chronic Urticaria Market Overview 
    6.1    Chronic Urticaria Market Historical Value (2017-2023) 
    6.2    Chronic Urticaria Market Forecast Value (2024-2032)
7.    Chronic Urticaria Market Landscape
    7.1    Chronic Urticaria Market: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Chronic Urticaria Market: Product Landscape
        7.2.1    Analysis by Drug Class 
        7.2.2    Analysis by Route of Administration
8.    Chronic Urticaria Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9.    Cost of Treatment
10.    Chronic Urticaria Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11.    Chronic Urticaria Market Segmentation -7MM
    11.1    Chronic Urticaria Market by Therapeutic Class
        11.1.1    Market Overview
        11.1.2    Antihistamines 
        11.1.3    H-2 Blockers
        11.1.4    Antidepressants 
        11.1.5    Monoclonal Antibodies 
        11.1.6    Others
    11.2    Chronic Urticaria Market by Route of Administration
        11.2.1    Market Overview
        11.2.2    Oral 
        11.2.3    Parenteral 
        11.2.4    Others
    11.3    Chronic Urticaria Market by Distribution Channel
        11.3.1    Market Overview
        11.3.2    Hospital Pharmacy
        11.3.3    Online Pharmacy
        11.3.4    Retail Pharmacy
        11.3.5    Others
    11.4    Chronic Urticaria Market by Region -7MM
        11.4.1    Market Overview
        11.4.2    United States
        11.4.3    EU-4 and the United Kingdom
        11.4.4    Japan
12.    United States Chronic Urticaria Market 
    12.1    U.S. Chronic Urticaria Market Historical Size (2017-2023)  
    12.2    U.S. Chronic Urticaria Market Forecast Size (2024-2032)  
    12.3    Market Size by Therapeutic Class
13.    EU-5 and the United Kingdom Chronic Urticaria Market
    13.1    EU-5 and the United Kingdom Chronic Urticaria Market Historical Size (2017-2023)  
    13.2    EU-5 and the United Kingdom Chronic Urticaria Market Forecast Size (2024-2032)  
    13.3    Market Size by Therapeutic Class
14.    Japan Chronic Urticaria Market
    14.1    Japan Chronic Urticaria Market Historical Size (2017-2023)  
    14.2    Japan Chronic Urticaria Market Forecast Size (2024-2032)  
    14.3    Market Size by Therapeutic Class
15.    Regulatory Framework
    15.1    Regulatory Overview
        15.1.1    US FDA
        15.1.2    EU EMA
        15.1.3    JAPAN PMDA
16.    Patent Analysis
    16.1    Analysis by Type of Patent
    16.2    Analysis by Publication year
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Patent Age
    16.5    Analysis by CPC Analysis
    16.6    Analysis by Patent Valuation 
    16.7    Analysis by Key Players
17.    Grants Analysis
    17.1    Analysis by year
    17.2    Analysis by Amount Awarded
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Grant Application
    17.5    Analysis by Funding Institute
    17.6    Analysis by NIH Departments
    17.7    Analysis by Recipient Organization 
18.    Clinical Trials Analysis
    18.1     Analysis by Trial Registration Year
    18.2    Analysis by Trial Status
    18.3    Analysis by Trial Phase
    18.4    Analysis by Therapeutic Area
    18.5    Analysis by Geography
19.    Funding and Investment Analysis
    19.1    Analysis by Funding Instances
    19.2    Analysis by Type of Funding
    19.3    Analysis by Funding Amount
    19.4    Analysis by Leading Players
    19.5    Analysis by Leading Investors
    19.6    Analysis by Geography
20.    Partnership and Collaborations Analysis
    20.1    Analysis by Partnership Instances
    20.2    Analysis by Type of Partnership
    20.3    Analysis by Leading Players
    20.4    Analysis by Geography
21.    Supplier Landscape
    21.1    Johnson & Johnson Private Limited
        21.1.1    Financial Analysis
        21.1.2    Product Portfolio
        21.1.3    Demographic Reach and Achievements
        21.1.4    Mergers and Acquisitions
        21.1.5    Certifications
    21.2    Novartis AG
        21.2.1    Financial Analysis
        21.2.2    Product Portfolio
        21.2.3    Demographic Reach and Achievements
        21.2.4    Mergers and Acquisitions
        21.2.5    Certifications
    21.3    Amneal Pharmaceuticals, Inc. 
        21.3.1    Financial Analysis
        21.3.2    Product Portfolio
        21.3.3    Demographic Reach and Achievements
        21.3.4    Mergers and Acquisitions
        21.3.5    Certifications
    21.4    Pfizer Inc. 
        21.4.1    Financial Analysis
        21.4.2    Product Portfolio
        21.4.3    Demographic Reach and Achievements
        21.4.4    Mergers and Acquisitions
        21.4.5    Certifications
    21.5    Mylan N.V
        21.5.1    Financial Analysis
        21.5.2    Product Portfolio
        21.5.3    Demographic Reach and Achievements
        21.5.4    Mergers and Acquisitions
        21.5.5    Certifications
    21.6    GlaxoSmithKline plc
        21.6.1    Financial Analysis
        21.6.2    Product Portfolio
        21.6.3    Demographic Reach and Achievements
        21.6.4    Mergers and Acquisitions
        21.6.5    Certifications
    21.7    Merck & Co., Inc.
        21.7.1    Financial Analysis
        21.7.2    Product Portfolio
        21.7.3    Demographic Reach and Achievements
        21.7.4    Mergers and Acquisitions
        21.7.5    Certifications
22.    Chronic Urticaria Market - Distribution Model (Additional Insight)
    22.1    Overview 
    22.2    Potential Distributors 
    22.3    Key Parameters for Distribution Partner Assessment 
23.    Key Opinion Leaders (KOL) Insights (Additional Insight)
24.    Company Competitiveness Analysis (Additional Insight)

    24.1    Very Small Companies
    24.2    Small Companies
    24.3    Mid-Sized Companies
    24.4    Large Companies
    24.5    Very Large Companies
25.    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

*Additional insights provided are customizable as per client requirements.

*The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124